Research suggests Celebrex risk lower than Vioxx

Share this article:
Celebrex appears to not carry the same heart risk as Merck's Vioxx, according to new research published this week in the medical journal Annals of Internal Medicine.
Researchers at the University of Pennsylvania found that Vioxx was 2.72 times as likely to be associated with a nonfatal first heart attack than Celebrex -- contradicting the claims of some scientists that all cox-2 medicines may carry similar dangers.
"What that implies is that all cox-2 inhibitors may not be the same," Stephen Kimmel, associate professor of medicine and epidemiology and lead author of the study, told the Associated Press.
However, University of Pennsylvania cardiologist and pharmacologist, Garret Fitzgerald, questioned whether the study proved anything new.
"It's not a clean bill of health for Celebrex," Fitzgerald said in an Associated Press report. "It's well recognized that these types of studies are not conclusive."
To find proof, Fitzgerald said, researchers would have to conduct a random study involving people who took Vioxx, people who took Celebrex and people who took placebo – all before they had heart attacks.   
Instead, researchers studied 1,718 patients in the Philadelphia area who had heart attacks and who were treated at one of 36 hospitals, and a comparison group of 6,800 people in the region.
The study was co-funded by Pfizer, Merck and the federal government.
Vioxx was withdrawn from the market on Sept. 30 after a study revealed the risk of heart attacks and stroke was doubled when the drug was taken for more than 18 months.
According to data from IMS Health, in October, sales of Celebrex topped $260 million – 63.5 percent of the market for cox-2 inhibitors.
Share this article:

Email Newsletters

More in News

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.

GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs

The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.

Valeant bids $47B for Allergan

Valeant bids $47B for Allergan

The deal would bring Allergan's Botox and Juvederm under the same roof as Restylane.